Teachers Advisors LLC grew its holdings in shares of Astrazeneca PLC (NYSE:AZN) by 8.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,019,248 shares of the company’s stock after acquiring an additional 81,934 shares during the period. Teachers Advisors LLC’s holdings in Astrazeneca PLC were worth $34,746,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of AZN. Meeder Asset Management Inc. acquired a new stake in Astrazeneca PLC during the 2nd quarter worth about $105,000. Salem Investment Counselors Inc. acquired a new stake in Astrazeneca PLC during the 1st quarter worth about $107,000. Tower Research Capital LLC TRC grew its holdings in Astrazeneca PLC by 3,782.0% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after acquiring an additional 3,782 shares during the period. Parallel Advisors LLC grew its holdings in Astrazeneca PLC by 27.1% during the 1st quarter. Parallel Advisors LLC now owns 4,526 shares of the company’s stock worth $138,000 after acquiring an additional 964 shares during the period. Finally, Bronfman E.L. Rothschild L.P. grew its stake in shares of Astrazeneca PLC by 71.2% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock valued at $145,000 after buying an additional 1,769 shares during the period. Hedge funds and other institutional investors own 14.17% of the company’s stock.

Astrazeneca PLC (NYSE AZN) opened at 32.42 on Tuesday. The company has a market cap of $82.09 billion, a PE ratio of 21.27 and a beta of 0.74. Astrazeneca PLC has a 52-week low of $25.55 and a 52-week high of $35.60. The firm’s 50 day moving average is $30.26 and its 200 day moving average is $31.79.

Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.87 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. During the same quarter in the prior year, the company earned $0.83 earnings per share. The business’s revenue was down 9.9% compared to the same quarter last year. Analysts forecast that Astrazeneca PLC will post $1.90 EPS for the current fiscal year.

The company also recently declared a None dividend, which was paid on Monday, September 11th. Stockholders of record on Friday, August 11th were issued a dividend of $0.44 per share. This represents a dividend yield of 2.98%. The ex-dividend date was Wednesday, August 9th. Astrazeneca PLC’s payout ratio is 44.92%.

Several analysts have recently commented on the company. Piper Jaffray Companies restated a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, August 9th. BidaskClub downgraded Astrazeneca PLC from a “sell” rating to a “strong sell” rating in a research note on Friday, August 4th. Investec upgraded Astrazeneca PLC from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Liberum Capital downgraded Astrazeneca PLC from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th. Finally, Cowen and Company restated a “hold” rating and issued a $34.00 target price on shares of Astrazeneca PLC in a research note on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $33.60.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/19/astrazeneca-plc-azn-holdings-increased-by-teachers-advisors-llc.html.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.